The molecular pathology of Barrett's esophagus.

The incidence of adenocarcinoma of the distal esophagus is rapidly increasing in the Western world. The histopathological sequence of (Barrett's) metaplasia, which develops as a consequence of chronic reflux, to dysplasia and then to carcinoma is well established for these tumors. In Barrett's esophagus a variety of molecular changes have been characterized and correlated with tumor initiation and progression. Among the early changes in premalignant stages of metaplasia are alterations of the transcripts of FHIT, a presumptive tumor suppressor gene which spans the common fragile site FRA3B. Mutations of p53 seem to accumulate mainly in the transition from low to high grade dysplasia. Inactivation of other tumor suppressor genes by mutation (APC, p16) or hypermethylation (p16) as well as amplification of oncogenes such as cerbB2 are relatively late events in the development of adenocarcinoma. Among the phenotypic changes in Barrett's esophagus are an expansion of the Ki67 proliferation compartment which correlates with the degree of dysplasia. Moreover, accumulation of rab11 molecules which are involved in membrane trafficking has been reported to be specific for the loss of polarity seen in low grade dysplasia. Reduced expression of the cadherin/catenin complex as well as increased expression of various proteases develop chiefly in invasive carcinomas. Despite the progress that has been made in the identification of molecular markers in Barrett's carcinoma, to date the histopathological diagnosis of high grade dysplasia in endoscopic biopsies remains the best predictor of invasive cancer. Immunohistochemistry applying a panel of antibodies including p53, Mib-1 or rab11 can be helpful to diagnose regenerative metaplastic epithelium or low and high grade dysplasia.

[1]  H. Nekarda,et al.  Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  J. V. van Lanschot,et al.  Clinical decision making in Barrett's oesophagus can be supported by computerized immunoquantitation and morphometry of features associated with proliferation and differentiation , 1998, The Journal of pathology.

[3]  D. Beer,et al.  Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinoma. , 1997, Cancer research.

[4]  J. Goldenring,et al.  Increased immunoreactivity for Rab11, a small GTP-binding protein, in low-grade dysplastic Barrett's epithelia. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[5]  N. Altorki,et al.  Expression of acidic fibroblast growth factor in Barrett's esophagus and associated esophageal adenocarcinoma. , 1997, The Journal of thoracic and cardiovascular surgery.

[6]  D. Beer,et al.  Frequent deletions of FHIT and FRA3B in Barrett's metaplasia and esophageal adenocarcinomas , 1997, Oncogene.

[7]  Jan-Gowth Chang,et al.  Aberrant FHIT transcripts in cancerous and corresponding non‐cancerous lesions of the digestive tract , 1997, International journal of cancer.

[8]  Suna Wang,et al.  FHIT gene alterations in esophageal cancer and ulcerative colitis (UC) , 1997, Oncogene.

[9]  G. Thomas,et al.  Loss of heterozygosity on chromosome 9 and p16 (MTS1, CDKN2) gene mutations in esophageal cancers , 1997, International journal of cancer.

[10]  N. Altorki,et al.  Epidemiology and molecular biology of Barrett's adenocarcinoma. , 1997, Seminars in surgical oncology.

[11]  W. Hop,et al.  Reduced expression of the cadherin–catenin complex in oesophageal adenocarcinoma correlates with poor prognosis , 1997, The Journal of pathology.

[12]  D. Wong,et al.  p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. , 1997, Cancer research.

[13]  V. Álvarez,et al.  Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. , 1997, Journal of clinical pathology.

[14]  R. Odze,et al.  Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[15]  W. Giaretti.  Aneuploidy Mechanisms in Human Colorectal Preneoplastic Lesions and Barrett’s Esophagus. Is There a Role for K-Ras and p53 Mutations? , 1997, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[16]  H. Appelman,et al.  Tumors of the Esophagus and Stomach , 1996 .

[17]  C. Moskaluk,et al.  p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. , 1996, Human pathology.

[18]  S. Kern,et al.  Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. , 1996, Cancer research.

[19]  A. Hagemeijer,et al.  Cytogenetic analysis of Barrett's mucosa and adenocarcinoma of the distal esophagus and cardia. , 1996, Cancer genetics and cytogenetics.

[20]  Carissa A. Sanchez,et al.  Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. , 1996, Oncogene.

[21]  L. Liotta,et al.  Barrett's esophagus: metaplastic cells with loss of heterozygosity at the APC gene locus are clonal precursors to invasive adenocarcinoma. , 1996, Cancer research.

[22]  J. Goldenring,et al.  Rab11 is an apically located small GTP-binding protein in epithelial tissues. , 1996, The American journal of physiology.

[23]  C. Croce,et al.  The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract Cancers , 1996, Cell.

[24]  J. Roth,et al.  Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. , 1996, The Journal of thoracic and cardiovascular surgery.

[25]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[26]  J. Sloan,et al.  Base transitions at CpG dinucleotides in the p53 gene are common in esophageal adenocarcinoma. , 1995, Cancer research.

[27]  J. Bartek,et al.  Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16 , 1995, Nature.

[28]  J. Field,et al.  Frequent loss of heterozygosity on chromosome 17 at 17q11.2-q12 in Barrett's adenocarcinoma. , 1995, British Journal of Cancer.

[29]  S. Nagata,et al.  The Fas death factor , 1995, Science.

[30]  F. Bosman,et al.  Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus , 1995, The Journal of pathology.

[31]  S. Steinberg,et al.  Expansion of the Ki‐67 proliferative compartment correlates with degree of Dysplasia in Barrett's esophagus , 1995, Cancer.

[32]  G. Thomas,et al.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.

[33]  V. Rusch,et al.  The management of high grade dysplasia and early cancer in Barrett's esophagus , 1994, Cancer.

[34]  H. Höfler,et al.  E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. , 1994, Cancer research.

[35]  J. Behrens.  Cadherins as determinants of tissue morphology and suppressors of invasion. , 1994, Acta anatomica.

[36]  Carissa A. Sanchez,et al.  p53 mutations in Barrett's adenocarcinoma and high-grade dysplasia. , 1994, Gastroenterology.

[37]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[38]  A. Mercurio,et al.  Poorly differentiated colon carcinoma cell lines deficient in alpha-catenin expression express high levels of surface E-cadherin but lack Ca(2+)-dependent cell-cell adhesion. , 1993, Cell adhesion and communication.

[39]  Patricia L. Blount,et al.  An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. , 1993, Gastroenterology.

[40]  D. Beer,et al.  Amplification and over‐expression of the EGFR and erbB‐2 genes in human esophageal adenocarcinomas , 1993, International journal of cancer.

[41]  Patricia L. Blount,et al.  Clonal ordering of 17p and 5q allelic losses in Barrett dysplasia and adenocarcinoma. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Leland Hartwell,et al.  Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells , 1992, Cell.

[43]  P. Pairolero,et al.  Barrett's esophagus with high-grade dysplasia: an indication for esophagectomy? , 1992, The Annals of thoracic surgery.

[44]  K. Lewin,et al.  Distribution of dysplasias and early invasive carcinoma in Barrett's esophagus. , 1992, Human pathology.

[45]  G. Sutherland.  Chromosomal fragile sites. , 1991, Genetic analysis, techniques and applications.

[46]  J. Fraumeni,et al.  Rising incidence of adenocarcinoma of the esophagus and gastric cardia. , 1991, JAMA.

[47]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[48]  H. Barr,et al.  Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. , 1998, The American journal of pathology.

[49]  T. Demeester,et al.  Barrett's esophagus. The significance of p53 in clinical practice. , 1997, Annals of surgery.

[50]  J. Crawford.  Membrane trafficking and the pathologist: esophageal dysplasia. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[51]  C. Férec,et al.  Molecular analysis of the TP53 gene in Barrett's adenocarcinoma , 1996, Human mutation.

[52]  J. Roth,et al.  Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. , 1994, American journal of surgery.

[53]  S. Spechler,et al.  Barrett's esophagus. , 1994, Seminars in oncology.

[54]  D. Notterman,et al.  The p53 tumor suppressor gene. , 1994, The Journal of laboratory and clinical medicine.

[55]  P. Blount,et al.  Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. , 1992, Gastroenterology.

[56]  B. Reid,et al.  Progression to cancer in Barrett's esophagus is associated with genomic instability. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[57]  S. Ming.  Tumors of the esophagus and stomach , 1973 .